Pasireotide
http://dbpedia.org/resource/Pasireotide an entity of type: Thing
باسيريوتيد (بالإنجليزية: Pasireotide) هو دواء يُستعمل في علاج:
* مرض كوشينج المعتمد على النخامية (منذ 14 ديسمبر 2012)
rdf:langString
Le pasiréotide est une molécule analogue synthétique de la somatostatine, inhibant l'action de l'hormone de croissance.
rdf:langString
パシレオチド（Pasireotide）は、米国、欧州、日本において、外科的治療に失敗した、あるいは不適格な患者のクッシング病の治療薬として承認されている希少疾病用医薬品である。パシレオチドは、他のソマトスタチンアナログと比較して、への親和性が40倍も高いソマトスタチンアナログである。筋肉内注射で用いられる。 主な副作用には、高血糖、糖尿病、下痢、腹痛（胃痛）、吐き気、胆石症、注射部位反応、疲労感などがある。
rdf:langString
Pasireotide é um fármaco da Novartis de marca comercial Signifor. Foi aprovado para ser utilizado no tratamento da doença de Cushing pelo FDA em dezembro de 2012. Nos estudos clínicos de fase III mostrou que a maioria dos pacientes testados conseguiu reduzir os níveis de cortisol na urina.
rdf:langString
Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Pasireotide was approved for Cushing's disease by the European Medicines Agency (EMA) in April 2012 and by the U.S. Food and Drug Administration (FDA) in December 2012.
rdf:langString
Il pasireotide è un peptide, analogo della somatostatina, caratterizzato da un'affinità per il recettore della somatostatina 5 quaranta volte maggiore dell'ormone endogeno e cinque volte maggiore rispetto agli altri analoghi. È un farmaco orfano sviluppato da Novartis, (Brand name: SIGNIFOR), studiato per la terapia della malattia di Cushing.
rdf:langString
rdf:langString
باسيريوتيد
rdf:langString
Pasiréotide
rdf:langString
Pasireotide
rdf:langString
パシレオチド
rdf:langString
Pasireotide
rdf:langString
Pasireotide
xsd:integer
31715666
xsd:integer
1040489030
rdf:langString
CB05
rdf:langString
H01
xsd:integer
58
xsd:integer
396091
xsd:integer
72312
xsd:integer
8117062
rdf:langString
DB06663
xsd:integer
66
rdf:langString
[-9--3-benzyl-12--2,5,8,11,14,17-hexaoxo-15-phenyl-6-[methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-carbamate
rdf:langString
D10147
rdf:langString
Rx-only
rdf:langString
POM
rdf:langString
Rx-only
xsd:integer
10
xsd:integer
9
rdf:langString
N
xsd:integer
9941444
rdf:langString
C1[C@H]OCNCCN
xsd:integer
1
rdf:langString
VMZMNAABQBOLAK-DBILLSOUSA-N
rdf:langString
SOM230
rdf:langString
Signifor, Signifor LAR
xsd:integer
98
rdf:langString
changed
xsd:integer
451604097
rdf:langString
changed
rdf:langString
باسيريوتيد (بالإنجليزية: Pasireotide) هو دواء يُستعمل في علاج:
* مرض كوشينج المعتمد على النخامية (منذ 14 ديسمبر 2012)
rdf:langString
Le pasiréotide est une molécule analogue synthétique de la somatostatine, inhibant l'action de l'hormone de croissance.
rdf:langString
Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. The most common side effects include hyperglycaemia (high blood sugar levels), diabetes, diarrhoea, abdominal pain (stomach ache), nausea (feeling sick), cholelithiasis (gallstones), injection site reactions, and tiredness. Pasireotide was approved for Cushing's disease by the European Medicines Agency (EMA) in April 2012 and by the U.S. Food and Drug Administration (FDA) in December 2012. Pasireotide LAR (the long-acting-release formulation) was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMA in September 2014.
rdf:langString
Il pasireotide è un peptide, analogo della somatostatina, caratterizzato da un'affinità per il recettore della somatostatina 5 quaranta volte maggiore dell'ormone endogeno e cinque volte maggiore rispetto agli altri analoghi. È un farmaco orfano sviluppato da Novartis, (Brand name: SIGNIFOR), studiato per la terapia della malattia di Cushing. Il farmaco ha mostrato un potenziale effetto terapeutico in uno studio clinico del 2010 condotto su 162 pazienti trattati con di parireotide (dosaggio di 2x 600 µg o 2x 900 µg al giorno). L'efficacia del trattamento è stata valutata con il dosaggio cortisolo libero urinario dopo sei mesi dal trattamento, dimostrandone una riduzione massima pari al 47,9%, unito a un miglioramento clinico in termini di pressione arteriosa, colesterolemia e perdita di peso.
rdf:langString
パシレオチド（Pasireotide）は、米国、欧州、日本において、外科的治療に失敗した、あるいは不適格な患者のクッシング病の治療薬として承認されている希少疾病用医薬品である。パシレオチドは、他のソマトスタチンアナログと比較して、への親和性が40倍も高いソマトスタチンアナログである。筋肉内注射で用いられる。 主な副作用には、高血糖、糖尿病、下痢、腹痛（胃痛）、吐き気、胆石症、注射部位反応、疲労感などがある。
rdf:langString
Pasireotide é um fármaco da Novartis de marca comercial Signifor. Foi aprovado para ser utilizado no tratamento da doença de Cushing pelo FDA em dezembro de 2012. Nos estudos clínicos de fase III mostrou que a maioria dos pacientes testados conseguiu reduzir os níveis de cortisol na urina.
rdf:langString
Pasireotide
xsd:integer
2018
rdf:langString
Rx-only
rdf:langString
yes
rdf:langString
B3
xsd:nonNegativeInteger
7211
rdf:langString
Signifor, Signifor LAR
xsd:string
396091-73-9
xsd:string
72312
xsd:string
DB06663
xsd:string
98H1T17066
xsd:string
D10147
xsd:string
9941444